Biotechnology leader Regeneron Pharmaceuticals is acquiring genetic testing firm 23andMe for $256 million following its bankruptcy filing. The deal excludes 23andMe’s telehealth subsidiary, Lemonaid ...

Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.

Me has faced an uncertain future after struggles to find a profitable business model and privacy concerns related to ...

Regeneron’s antibody cocktail seems to reduce levels of coronavirus and improve symptoms in patients, according to early test results. This first data comes from a descriptive analysis from the ...

Thanks to a drug cocktail including Regeneron’s antibody therapy ... Schleifer told CBS News’ Face the Nation: “So the president's case is a case of one, and that's what we call a case ...

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection ...

Fox News is an independent company that does not claim any ownership of the term "Wordle". "Wordle" is only used for descriptive purposes and we do not claim any official association with Wordle.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Regeneron’s bid to join the market for BCMA-targeted bispecific antibodies for multiple myeloma is nearing a conclusion, with the FDA starting a priority review of its linvoseltamab drug candidate.

Regeneron and Illumina have joined a major investment in health data specialist Truveta that will support the creation of a major new genome project. The two companies, along with 17 US health ...

Regeneron is the second pharma group to sign up for access to data from a remote study run by health technology firm Koneksa that is exploring the use of digital biomarkers to track patients with ...

Details: Diggs, one of the top receivers on the market, visited the Patriots on Thursday, according to FOX Sports' Jordan Schultz. While the two sides did not agree to a deal, they will stay in ...